Top Tweets for #Nurecombo
Tumor mutational burden predicts the outcome of patients with muscle-invasive bladder cancer undergoing immune-checkpoint inhibitor-based neoadjuvant therapy - a combined analysis of #PURE01 #SURE02 #NureCombo @CMercinelli @Anto_cigliola @BrigidaMaiorano et al. @SanRaffaeleMI @MyUniSR #TMB @FoundationATCG https://t.co/xTtHLnDsJT
Out now on @urotoday my interview on updated results of #NureCombo trial presented at last @ASCO annual meeting in #Chicago
Thanks again to dr Zachary Klaassen and all the UroToday team for the chance to share our work on #bladdercancer
https://t.co/aTdjEsn2Zt
Proud of my productive team of #GUOncology @SanRaffaeleMI @MyUniSR occupying the GU Poster Session @ASCO #ASCO25 #PURE01 #SURE01 #NureCombo @ConquerCancerFd @BrigidaMaiorano @vale_tateo @Anto_cigliola @CMercinelli
Key takeaways:
- SURE01: Luminal subtype & Top1 expression linked to SG benefit in MIBC
- PURE01: Claudin Low subtype linked to flat OS curve at 5y
- NureCombo: same as above
Thanks @VJOncology for the interview today at #ASCO25
It was a pleasure to discuss #NUREcombo updated results & share insights on our work on #bladdercancer at @SanRaffaeleMI
Grateful for the opportunity!
Many thanks to @CMercinelli for speaking with us at #ASCO25 today.
🌟The NURE-Combo study
🌟Patient selection for intensive multimodal approaches
🌟Managing immunotherapy toxicities
Coming soon to https://t.co/ys1d8pE8Am🎥
@ASCO #BlcSM #UroOnc
Mixed abstract titles #ASCO25 from our rising stars @MyUniSR @SanRaffaeleMI
- #PURE01 hits again with 5y FUP results presented by @vale_tateo
- #NureCombo OS and bmks by @CMercinelli also #MeritAward recipient @ConquerCancerFd
- #SURE01 interim EFS/OS results from neoadj SG in pts with MIBC by @BrigidaMaiorano
@urotoday @OncoAlert @Anto_cigliola @Larvol @ASCO
Deeply honored to have been selected for the #ASCO2025 #MeritAward for our work on #NureCombo ➡️ Once again, many thanks to the @ConquerCancerFd and to my mentor, Prof. @AndreaNecchi for the incredible opportunity! @SanRaffaeleMI
See you in Chicago!✨ @ASCO
Congratulations to the 2025 ASCO Annual Meeting Merit Award and Special Merit Award recipients. These awards will support 137 students and trainees who are first authors on abstracts selected for presentation at #ASCO25. View the full list of recipients: https://t.co/CWLUxr2cVA
Honored to receive this award for #NureCombo trial! Thank you Dr @g_procopio_ for this recognition!
#GUoncology
At the end of the Rare Histology session, it’s time to honor Dr. @CMercinelli with the award for the Best Publication in Urological
Oncology. Congratulations on this well-deserved recognition!
#UrologicalOncology
#ExcellenceInResearch
#ResearchAward #Oncology
At #GURetreat24, impressive portfolio of #bladdercancer studies at @SanRaffaeleMI presented by @Anto_cigliola. #NURECombo published by @CMercinelli in @JCO_ASCO, #SURE01 presented by @BrigidaMaiorano & #NEOGDFATHER ongoing (w cool supportive data for GDF15 published in @Nature). So impressed at how @AndreaNecchi supports his fellows & junior faculty!
Finally out on @JCO_ASCO #NureCombo!Neoadj Nivo/ABX achieved a ypT</=1N0-x in 70.9% pts.
In the ITT population 32.3% pCR ➡️ by including those who underwent reTURBT only, 38.7% pCR. Thanks to my mentor @AndreaNecchi and the whole team without whom it would not have been possible
Out in @JCO_ASCO our next piece of the neoadjuvant puzzle in muscle-invasive #bladdercancer. Taxanes could be another good choice of backbone chemo to combine with IO, overcoming the known limits of platinum.
#NureCombo provided Nivo/ABX x4 > RC > adj Nivo x13. N=31.
22 pts (70.9%, 95%CI: 51.9-85.8%) achieved a ypT</=1N0-x response.
In the ITT population, 10 pts (32.3%, 95% CI: 16.7-51.4) achieved an ypT0N0 response. By including those who underwent reTURBT, 12 pts (38.7%; 95%CI: 22-56) achieved an ypT0N0-x response.
@CMercinelli @vale_tateo @Anto_cigliola @BrigidaMaiorano @GiorgioBre @FDeCobelli @gio_pasto_real @BasileG_ @UroMoschini @DanieleRaggi83 @Albert0Briganti @SanRaffaeleMI @MyUniSR @urotoday @Medscape @ASCO
https://t.co/uCDvloixL6
Here we go with our @MyUniSR medical student @gio_pasto_real presenting #NureCombo neoadj trial biomarker data. Congratulations the future is bright! @SanRaffaeleMI @CMercinelli @Anto_cigliola @vale_tateo @ASCO #ASCO24 @urotoday
Watch Dr Chiara Mercinelli discuss the exciting first results of the NURE-Combo trial, showcasing a promising new treatment protocol for MIBC👉https://t.co/g1bGvsCz31 #BladderCancer #Oncology #NURECombo #CancerResearch #EAU24
Fantastic podium session at #AUA24 yesterday, delving deep into the latest insights on #MIBC. So much valuable discussion and learning! Grateful for the opportunity to present results from #NureCombo trial
@AmerUrological @MyUniSR @
@PGrivasMDPhD Excellent talks by @sonpavde on practice changing Checkmate901 trial & @CMercinelli on NURE trial biomarkers! @AmerUrological #AUA24 @AndreaNecchi @shilpaonc @UroDocAsh @Uromigos @Anto_cigliola @SanRaffaeleMI @SpiessPhilippe @karima_oualla @neerajaiims @montypal
@CMercinelli rocks the stage at #EAU24 presenting the primary outcomes of #NureCombo study investigating Nivo+Abraxane > RC > adjuvant nivo in #MIBC
70% pT<2 responses, pretty good tolerability @SanRaffaeleMI @MyUniSR @Uroweb @urotoday
It has been an honor to present today #NureCombo trial at @ASCO #GU24.
Great results with neoadj nivo/abraxane followed by adj nivo in MIBC, with 38.7% ypT0N0
@AndreaNecchi @SanRaffaeleMI
Stellar talk (second one) by @Anto_cigliola on the utility of PET to stage MIBC and evaluate response to neoadj Rx #PURE01 #NureCombo #SURE01 @CMercinelli @vale_tateo @SanRaffaeleMI @MyUniSR
Our superstars @CMercinelli @vale_tateo leading the Poster Session at #GU24 #WomeninGUcancers @ASCO @SanRaffaeleMI @MyUniSR @Anto_cigliola @ewanagibb #PURE01 #NureCombo #MeritAward
It was my pleasure to present the results of the first Interim analysis of #Nurecombo trial at #HSRscientificretreat2023 in #Baveno
Encouraging data of the combination Nivo-abraxane as a perioperative neoadj-adj strategy in T2-T4aN0M0 MIBC.
@shilpaonc @SUO_YUO @CleClinicMD @sonpavde @neerajaiims @maughanonc @ewanagibb @Huntsman_GU @tompowles1 @JoshMeeks Great work! Would be very important to compare biomarkers from your trial with those from #NureCombo trial. Does GC vs Abraxane have distinct combination effect with nivo?
A key question
Promising early signals of activity from #NureCombo trial (Nivo-Abraxane). Major path responses seen in 72%.
Following the path of #PEANUT study.
Is taxable a better chemo partner?
#GUOncology #Retreat22 @SanRaffaeleMI @MyUniSR @urotoday @DanieleRaggi83 @LauraMarandino
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.7M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.6M followers